Market Overview

Has Synergy Pharmaceuticals Become A Takeout Candidate Following 2 Recent Phase 3 Trial Successes?

Share:
Has Synergy Pharmaceuticals Become A Takeout Candidate Following 2 Recent Phase 3 Trial Successes?

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) has announced the results from its second pivotal Phase 3 trial for plecanatide in constipation-predominant irritable bowel syndrome (IBS-C), reconfirming the robust efficacy and clean side effect profile of the drug candidate.

BTIG’s Timothy Chiang maintains a Buy rating on the company, with a price target of $11.

Second Successful Trial

The overall response rate for the second Phase 3 trial was 30 percent, which was higher than the rate reported in the first Phase 3 study, with diarrhea incidence continuing in the low- to mid-single digits.

The results for the second Phase 3 study were highly statistically significant for both the 3mg and 6mg doses evaluated, with the incidence of adverse effects remaining low in both groups.

Sales Potential

The analyst expects Synergy Pharmaceuticals to file a supplemental NDA for plecanatide in Q1 2017 and believes that the drug would receive FDA approval and witness meaningful sales in the United States.

The sales estimates for plecanatide for 2017 to 2020 are $35 million, $150 million, $330 million and $480 million, respectively.

“We remain positive on SGYP shares, and believe larger pharma companies could see value in acquiring the Co. for plecanatide,” Chiang mentioned.

Latest Ratings for SGYP

DateFirmActionFromTo
Oct 2018BTIG ResearchDowngradesBuyNeutral
Oct 2018Canaccord GenuityDowngradesBuyHold
Jan 2018OppenheimerDowngradesOutperformPerform

View More Analyst Ratings for SGYP
View the Latest Analyst Ratings

 

Related Articles (SGYP)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas M&A News Health Care Reiteration FDA Best of Benzinga

Latest Ratings

StockFirmActionPT
TDOCDA DavidsonMaintains275.0
ITRIOppenheimerMaintains127.0
CLHOppenheimerMaintains95.0
TDOCOppenheimerMaintains270.0
CHEOppenheimerMaintains580.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com